Group 1 - The stock of Basilea Pharmaceutica (02616) has increased by over 5%, currently trading at 10.7 HKD with a transaction volume of 301 million HKD [1] - The Government of Singapore Investment Corporation (GIC) has increased its stake in Basilea by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD, raising its ownership from 0.00% to 5.49% [1] - The company continues to implement strategic collaborations, with Shugli monoclonal antibody expected to submit a new indication application to the European Medicines Agency (EMA) by March 2025 for treating unresectable stage III NSCLC patients [1] Group 2 - In January 2025, the company reached a commercialization strategic cooperation agreement with SteinCares for 10 Latin American countries, and in July 2025, it established a strategic partnership with Gentili for 23 countries in Western Europe and the UK [1] - The international influence of Shugli monoclonal antibody has expanded to over 60 countries globally [1]
基石药业-B再涨超5% GIC近期增持股份 公司战略合作持续落地